Brahmins did not start untouchability: Pejawar seer

Mangaluru, Mar 12: Deputy Commissioner Sindhu B Rupesh on Thursday said that the test reports of the 35-year-old passenger from Dubai have shown no signs of either Coronavirus (COVID-19) or H1N1.

In statement issued here Ms Rupesh said that the passenger has now been discharged from the Bantwal hospital. He has been asked to stay at home quarantined for the next 14 days.

The passenger, who had been diagnosed with fever after he arrived at the airport from Dubai on March 8, had left the Government Wenlock Hospital in the early hours of March 9 refusing to undergo tests.

Later, he was traced and admitted to the hospital in Bantwal and his throat swab samples had been sent to Viral Research Diagnostic Laboratory (VRDL) in Hassan Institute of Medical Sciences.

Meanwhile, throat swab samples of six patients were also found negative for COVID-19.

As many asf 49 people were under quarantine in the district of which five have completed the 28-day cycle.

All passengers arriving by international flights and those in contact with them should voluntarily report to the district health team and undergo self-quarantine for 14 days. If there were symptoms of cough, cold and fever, they should undergo tests for COVID-19. If the reports were positive for COVID-19, then they have to stay in the isolation ward of the Government Wenlock Hospital or in the seven select private hospitals for 28 days.

Screening facility at the airport has been strengthened by posting doctors from seven private medical colleges on rotation basis. These doctors would be in addition to the medical officer at the airport. An ambulance has been placed at the airport exclusively to shift people to the hospitals, she added.

The State government has issued a notification on Wednesday authorising Deputy Commissioners to get the affected admitted by force, if necessary.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.